Blood pressure disorders during Parkinson's disease: Epidemiology, pathophysiology and management

Expert Review of Neurotherapeutics

Volumn 6, Issue 8, 2006, Pages 1173-1180

  Pathak, Atul ^a,b   Senard, Jean Michel ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b INSERM   (France)

Author keywords

Autonomic failure; Orthostatic hypotension; Parkinson's disease; Supine hypertension

Indexed keywords

ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLONIDINE; DILTIAZEM; DOPAMINE RECEPTOR STIMULATING AGENT; EPLERENONE; ERGOT DERIVATIVE; FLUDROCORTISONE; GLYCERYL TRINITRATE; GUANFACINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYPERTENSIVE AGENT; MIDODRINE; MINERALOCORTICOID; MINOXIDIL; NEOSTIGMINE; NIFEDIPINE; NITRIC ACID DERIVATIVE; PHYSOSTIGMINE; PYRIDOSTIGMINE;

AUTONOMIC DYSFUNCTION; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; HYPERTENSION; HYPOTENSION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT EDUCATION; POSTPRANDIAL STATE; PRESSORECEPTOR REFLEX; REVIEW; SUPINE POSITION; SUSTAINED DRUG RELEASE; SYMPATHETIC TONE;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; HYPOTENSION, ORTHOSTATIC; PARKINSON DISEASE;

EID: 33747173719     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.8.1173     Document Type: Review

References (63)

1. Mathias CJ. The classification and nomenclature of autonomic disorders: ending chaos, resolving conflict and hopefully achieving clarity. Clin. Auton. Res. 5(6), 307-310 (1995).
2. Korczyn AD. Autonomic nervous system disturbances in Parkinson's disease. In: Advances in Neurology: Parkinson's Disease: Anatomy, Pathology and Therapy. StreiflerMB, Korczyn AD, Melamed E, Youdim MBH (Eds). Raven Press, NY, USA, 53, 463-468 (1990).
3. Pathak A, Senard JM. Pharmacology of orthostatic hypotension in Parkinson's disease: from pathophysiology to management. Exp. Rev. Cardiovasc. Ther. 2(3), 89-99 (2004). • Recent review on orthostatic and postprandial hypotension and their treatment in Parkinson's disease (PD).
4. Rutan GH, Hermanson B, Bild DE, Kittner SJ, LaBaw F, Tell GS. Orthostatic hypotension in the older adults. The cardiovascular health study. Hypertension 19(6), 508-519 (1992).
5. Raïha I, Luutonen S, Piha J, Seppanen A, Toikka T, Sourander L. Prevalence predisposing factors, and prognosis importance of postural hypotension. Arch. Intern. Med. 155(9), 930-935 (1995).
6. Elmstahl S, Rosen I. Postural hypotension and EEG variables predict cognitive decline: results from a 5-year follow-up of healthy elderly women. Dement. Geriatr. Cogn. Disord. 8(3), 180-187 (1997).
7. Eigenbrodt ML, Rose KM, Couper DJ, Arnett DK, Smith R, Jones D. Orthostatic hypotension as a risk factor for stroke. The Atherosclerosis Risk in Communities (ARIC) study, 1987-1996. Stroke 31(10), 2307-2313 (2000).
8. Rose KM, Tyroler HA, Nardo CJ et al. Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis Risk in Communities Study. Am. J. Hypertens 13(6), 571-578 (2000).
9. Pathak A, Lapeyre-Mestre M, Montastruc JL, Senard JM. Heat-related morbidity in patients with orthostatic hypotension and primary autonomic failure. Mov. Disord. 20(9), 1213-1219 (2005).
10. Masaki KH, Schatz IJ, Burchfiel CM et al. Orthostatic hypotension predicts mortality in elderly men. The Honolulu heart program. Circulation 98(21), 2290-2295 (1998).
11. Luukinen H, Koski K, Laippala P, Kivela SL. Prognosis of diastolic and systolic orthostatic hypotension in older persons. Arch. Intern. Med. 159(3), 273-280 (1999).
12. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Neurology 46(5), 1470 (1996).
13. Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. In: Advances in Neurology. Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (Eds). Raven Press, New York, USA, 609-612 (1993).
14. Wenning GK, Scherfler C, Granata R et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J. Neurol. Neurosurg. Psychiatry 67(5), 620-623 (1999).
15. van Dijk JG, Haan J, Zwinderman K, Kremer B, van Hilten BJ, Roos RA. Autonomic nervous system dysfunction in Parkinson's disease: relationship with age, medication, duration and severity. J. Neurol. Neurosurg. Psychiatry 56(10), 1090-1095 (1993).
16. Senard JM, Raï S, Lapeyre-Mestre M et al. Prevalence of orthostatic hypotension in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 63(5), 584-589 (1997).
17. Desboeuf K, Grau M, Riche F et al. Prevalence and costs of parkinsonian syndromes associated with orthostatic hypotension. Therapy (2006) (In press).
18. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiogical abnormalities. Lancet Neurol. 2(11), 669-676 (2003). • Comprehensive paper on the mechanisms of blood pressure disorders in PD.
19. Kimber JR, Watson L, Mathias CJ. Distinction of Parkinson's disease from multiple system atrophy by stimulation of growth-hormone release with clonidine. Lancet 349(9069), 1877-1881 (1997).
20. Senard JM, Rascol O, Durrieu G et al. Effects of yohimbine on plasma catecholamine levels in orthostatic hypotension related to Parkinson's disease or multiple system atrophy. Clin. Neuropharmacol. 16(1), 70-76 (1993).
21. 123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 53(5), 1020-1025 (1999).
22. Takatsu H, Nishida H, Matsuo H et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J. Nucl. Med. 41(1), 71-77 (2000).
23. Courbon F, Brefel-Courbon C, Thalamas C et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov. Disord. 18(8), 890-897 (2003).
24. Goldstein DS, Eldadah BA, Holmes C et al. Neurocirculatory abnormalities in Parkinson's disease with orthostatic hypotension. Independence from levodopa treatment. Hypertension 46 (6), 1333-1339 (2005).
25. Mathias CJ. Postprandial hypotension. Pathophysiological mechanisms and clinical implications in different disorders. Hypertension 18(5), 694-704 (1991).
26. Fisher AA, Davis MW, Srikusalanukul W, Budge MM. Postprandial hypotension predicts all-cause mortality in older, low-level care residents. J. Am. Geriatr. Soc. 53(8), 1313-1320 (2005).
27. Chaudhuri KR, Ellis C, Love-Jones S et al. Postprandial hypotension and parkinsonian state in Parkinson's disease. Mov. Disord. 12(6), 877-884 (1997).
28. Senard JM, Chamontin B, Rascol A, Montastruc JL. Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension. Clin. Auton. Res. 2(2), 99-104 (1992).
29. Verdecchia P. Prognostic value of ambulatory blood pressure. Hypertension 35, 844-851 (2000)
30. Fernandez HH, Lapane KL. Predictors of mortality among nursing home residents with a diagnosis of Parkinson's disease. Med. Sci. Monit. 8(4), CR241-CR246 (2002).
31. Korchounov A, Kessler K, Yakhno NN, Damulin IV, Schipper HI. Determinants of autonomic dysfunction in idiopathic Parkinson's disease. J. Neurol. 252, 1530-1536 (2005).
32. Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 42(2), 136-142 (2003). • Depicts differences in autonomic activity between patients suffering from PD, multiple-system atrophy and pure autonomic failure. Additionally, it demonstrates that supine hypertension can be observed in all these conditions and can be worsened by fludrocortisone.
33. Robertson D, Hollister AS, Biaggioni I, Netterville JL, Mosqueda-Garcia R, Robertson RM. The diagnosis and treatment of baroreflex failure. N. Engl. J. Med. 329(20), 1449-1455 (1993).
34. Shannon JR, Jordan J, Diedrich A et al. Sympathetically mediated hypertension in autonomic failure. Circulation 101(23), 2710-2715 (2000). • Strongly suggests that despite impaired autonomic function, residual sympathetic activity accounts for supine hypertension in multiple-system atrophy and pure autonomic failure.
35. Senard JM, Valet P, Durrieu G et al. Adrenergic supersensitivity in parkinsonians with orthostatic hypotension. Eur. J. Clin. Invest. 20(6), 613-619 (1990).
36. Estan L, Senard JM, Tran MA, Montastruc JL, Berlan M. Reserpine induces vascular α2-adrenergic supersensitivity and platelet α2-adrenoceptor up-regulation in dog. Br. J. Pharmacol. 101(2), 329-336 (1990).
37. Shannon J, Jordan J, Costa F, Robertson RM, Biaggioni I. The hypertension of autonomic failure and its treatment. Hypertension 30(5), 1062-1067 (1997).
38. Ibrahim MM, Tarazi RC, Dustan HP, Bravo EL. Idiopathic orthostatic hypotension: circulatory dynamics in chronic autonomic insufficiency. Am. J. Cardiol. 34, 288-294 (1974).
39. Kronenberg MW, Forman MB, Onrot J, Robertson D. Enhanced left ventricular contractility in autonomic failure: assessment using pressure-volume relations. J. Am. Coll. Cardiol. 15(6), 1334-1342 (1990).
40. Biaggioni I, Garcia F, Inagami T, Haile V. Hyporeninemic normoaldosteronism in severe autonomic failure. J. Clin. Endocrinol. Metab. 76(3), 580-586 (1993).
41. Ten Harkel AD, van Lieshout JJ, Wieling W. Treatment of orthostatic hypotension with sleeping in the head-up tilt position and in combination with fludrocortisone. J. Intern. Med. 232(2), 139-145 (1992).
42. Hakamäki T, Rajala T, Lehtonen A. Ambulatory 24-hour blood pressure recordings in patients with Parkinson's disease with or without fludrocortisone. Int. J. Clin. Pharmacol. Ther. 36(7), 367-370 (1998).
43. McClellan KJ, Wiseman LR, Wilde MI. Midodrine: a review of its therapeutical use in the management of orthostatic hypotension. Drugs & Aging 12(1), 76-86 (1998).
44. Desboeuf K, Senard JM, Pavy-Le-Traon A et al. Clinical practice survey of midodrine prescribing in a University hospital. Therapy 55(5), 613-617 (2000).
45. Pathak A, Raoul V, Montastruc JL, Senard JM. Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France. Eur. J. Clin. Pharmacol. 61(5-6), 471-474 (2005). • Shows that the benefit:risk ratio of drugs used in orthostatic hypotension is poorly known.
46. de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch. Neurol. 62(8), 1265-1269 (2005).
47. Fall PA, Saleh A, Fredrickson M, Olsson JE, Granérus AK. Survival time, mortality, and causes of death in elderly patients with Parkinosn's disease: a 9-year follow-up. Mov. Disord. 18(11), 1312-1316 (2003).
48. Donnan PT, Steinke DT, Stubbings C, Davey PG, MacDonald TM. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology 55(12), 1785-1789 (2000).
49. Wilcox CS, Aminoff MJ, Slater JD. Sodium homeostasis in patients with autonomic failure. Clin. Sci. Mol. Med. 53(4), 321-328 (1977).
50. Davidson C, Smith D, Morgan DB. Diurnal pattern of water and electrolyte excretion and body weight in idiopathic orthostatic hypotension. The effect of three treatments. Am. J. Med. 61(5), 709-715 (1976).
51. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21(6), 1011-1053 (2003).
52. Shibao C, Gamboa A, Diedrich A, Biaggioni I. Management of hypertension in the setting of autonomic failure. A pathophysiological approach. Hypertension 45(6), 469-476 (2005). • Clearly reports differences in response to drugs between different forms of autonomic failure.
53. Jordan J, Shannon JR, Pohar B et al. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J. Am. Soc. Nephrol. 10(1), 35-42 (1999).
54. Gaudiot N, Jaubert AM, Charbonnier E et al. Modulation of white adipose tissue lipolysis by nitric oxide. J. Biol. Chem. 273(22), 13475-13481 (1998).
55. Harmancey R, Senard JM, Pathak A et al. The vasoactive peptide adrenomedullin is secreted by adipocytes and inhibits lipolysis through NO-mediated β-adrenergic agonist oxidation. FASEB J. 19(8), 1045-1047 (2005).
56. Victor RG, Talman WT. Comparative effects of clonidine and dihydroergotamine on venomotor tone and orthostatic tolerance in patients with severe hypoadrenergic orthostatic hypotension. Am. J. Med. 112(5), 361-368 (2002).
57. Senard JM, Arias A, Berlan M, Tran MA, Rascol A, Montastruc JL. Pharmacological evidence of α1- and α2-adrenergic supersensitivty in orthostatic hypotension due to spinal cord injury: a case report. Eur. J. Clin. Pharmacol. 41(6), 593-596 (1991).
58. Brahmbhatt R, Baggaley P, Hockings B. Normalization of blood pressure in a patient with severe orthostatic hypotension and supine hypertension using clonidine. Hypertension 37(6), E24 (2001).
59. Park KH, Long JP, Cannon JG. Reversal of antihypertensive agent-induced postural hypotension with physostigmine. Arch. Int. Pharmacodyn. 311, 155-165 (1991).
60. Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J. Neurol. Neurosurg. Psychiatry 74(9), 1294-1298 (2003). • Suggests that pyridostigmine could improve orthostatic hypotension without inducing or worsening supine hypertension.
61. Senard JM. Pyridostigmine in the treatment of orthostatic hypotension. Clin. Auton. Res. 15(6), 421-422 (2005).
62. Verhaeverbeke I, Mets T. Drug-induced orthostatic hypotension in the elderly. Avoiding its onset. Drug Safety 17(2), 105-118 (1997).
63. Randomized, single-blind, placebo-controlled crossover study investigating the effects on supine systolic blood pressure and on pressure natriuresis http://clinicaltrials.gov.